Tirzepatide Weight Loss: What Studies Found

What did the Tirzepatide weight studies count?

Large phase 3 studies, done late in testing, counted lost weight and side effects. The people had obesity, and some didn't have type 2 diabetes; keep that difference in mind when comparing them with your health.

At the highest approved amount, 15 mg, people lost 20.9 percent on average; the study ran for 72 weeks. People given placebo, which has no active drug, lost 3.1 percent; another study compared tirzepatide with semaglutide, a different weekly weight shot. Average losses were 20.2 percent and 13.7 percent; Tirzepatide had the larger loss.

Tirzepatide weight loss numbers describe whole groups; they can't say how much you will lose.

The sections below give each group's size, time, and amount.

What did SURMOUNT-1 find about Tirzepatide weight loss?

SURMOUNT-1 was a phase 3 study lasting seventy-two weeks; it came late in testing. The adults and study staff didn't know who received active medicine; chance placed 2,539 adults into groups. They had obesity, meaning a BMI of 30 or more. Some had a BMI of 27 or more plus an illness linked with excess weight; none had type 2 diabetes. They used tirzepatide at 5, 10, or 15 mg each week, or placebo; during a 20-week period, the amount rose in planned steps.

By week 72, the 5 mg group had lost 15.0% on average; the 10 mg group lost 19.5%. The 15 mg group lost 20.9%, while the placebo group lost 3.1% ^[4]. At each amount, more people lost at least 5%, 10%, 15%, and 20%. About one in three people at 15 mg lost at least 25% of their weight.

A longer SURMOUNT-1 review followed people who began with prediabetes; this means sugar is high but hasn't reached diabetes. Their weight stayed lower; fewer went on to type 2 diabetes ^[35].

SURMOUNT-3 followed 579 people who had already lost at least 5%. First, they completed a 12-week food and activity plan. Tirzepatide users then lost another 18.4% by 72 weeks. Placebo users gained 2.5%. The difference was 20.8 percentage points ^[42].

A smaller SURMOUNT-1 group had body scans. Fat made up about 75% of lost weight. Lean tissue, including muscle, made up about 25% ^[14]. Your own split may differ.

What did SURMOUNT-5 show about Tirzepatide results?

The 751 adults in SURMOUNT-5 knew which medicine they received. All had obesity without type 2 diabetes. Chance placed each adult in a drug group. Each then used the highest amount their bodies could handle. Tirzepatide amounts were 10 or 15 mg. Semaglutide, another weekly weight shot, was 1.7 or 2.4 mg. Both were used each week for 72 weeks.

At week 72, tirzepatide users had lost 20.2% on average. Semaglutide users had lost 13.7%. Chance was an unlikely reason for the difference ^[5]. Tirzepatide also took more off the waist. More users lost at least 10%, 15%, 20%, and 25%.

A review joined 31 studies with over 35,000 people. Tirzepatide at 15 mg placed among the top three medicines for weight loss. Compared with placebo, it gave the highest rate of at least 15% loss ^[43]. A 95% certainty check, which asks whether chance might explain a finding, supported the ranking. Because it compared separate studies, the review gives you a less certain answer than one direct test.

What else changed as Tirzepatide weight loss grew?

A later SURMOUNT-1 review sorted people by weight loss. Heart and sugar readings improved more as loss grew. Among those losing at least 35%, the top blood-pressure number fell 14.2 millimeters of mercury on the cuff scale. The bottom number fell 9.2 millimeters of mercury. Waist size fell 32.4 centimeters. A blood test suggested their bodies resisted insulin 59.7% less ^[44]. The three-month sugar test improved even with smaller losses. Cholesterol and other fats measured in blood improved mainly after losses over 10%.

Some people gained weight after stopping the drug. SURMOUNT-4 moved one group to placebo. That group gained, while people staying on tirzepatide lost more ^[22]. As pounds returned, signs of heart and sugar risk grew worse ^[23]. A short course may not keep its gains for you.

A review joined 6 studies with 4,531 people. At 10 and 15 mg, tirzepatide improved people's reports about walking and daily tasks. One form had 36 questions about what their bodies let them do. Another asked how weight affected home life ^[45]. These answers came from daily experience, not a lab test.